Danaher Corporation (NYSE:DHR) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

On March 3, 2026, Danaher Corporation (NYSE:DHR) presented its 2026 strategic vision at the TD Cowen 46th Annual Health Care Conference. CEO Rainer Blair projected revenue growth of 3%-6% for 2026, driven by the bioprocessing segment. Also, the company anticipates a 100-basis-point operating margin expansion. Additionally, the Masimo acquisition is expected to expand the margins and provide high single-digit returns by year five. The management further projects a revenue impact of $75 million to $100 million from market shifts in China. However, the company expressed optimism, citing long-term opportunities in AI-based drug development and domestic reshoring initiatives.

Separately, on February 24, 2026, Danaher Corporation (NYSE:DHR) announced the approval from its Board of Directors to pay a regular quarterly cash dividend of $0.40 per share of its common stock. The company’s shareholders of record on March 27, 2026, will be eligible to receive the dividend that will be paid on April 24, 2026.

Founded in 1984, Danaher Corporation (NYSE:DHR) is a leading global innovator in life sciences and diagnostics. Its headquarters is in Washington, D.C.

While we acknowledge the potential of DHR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None. Follow Insider Monkey on Google News.